Actuate Therapeutics has received a Nasdaq warning after its share price stayed below the exchange’s $1 minimum for 30 consecutive business days. The notice does not immediately affect the stock’s listing, but the company now faces a deadline to restore compliance while it is also working to resolve a separate Nasdaq listing deficiency.
-
Deadline to lift the share price: Actuate has until April 26, 2027, to regain compliance. Its closing bid price must be at least $1 per share for at least 10 consecutive business days during that period, and the company must continue to meet Nasdaq’s other applicable listing requirements.
-
A possible additional period: If Actuate misses the deadline, it may qualify for another 180 days by seeking to transfer its shares to the Nasdaq Capital Market. That option depends on meeting the market-value and other initial listing standards for that market, apart from the minimum bid-price rule, and notifying Nasdaq of its intent to address the shortfall.
-
A separate listing shortfall remains: Actuate also has until January 11, 2027, to meet Nasdaq’s minimum market value of listed securities requirement. The new share-price notice does not change that deadline. The separate deficiency may also affect whether the company qualifies for an additional period to address its share price.
-
Trading continues for now: The common stock remains listed on the Nasdaq Global Market and trades under the symbol ACTU. If Actuate does not meet the applicable requirements within the available compliance periods, its shares could be delisted.
Investor implications: Actuate is addressing two distinct Nasdaq requirements at once: the minimum share price and the minimum market value of listed securities. The stock’s listing is not currently suspended, but continued Nasdaq listing depends on the company resolving both deficiencies or qualifying for additional time.